Investors

IR Overview

IR Overview

Cómo funcionan nuestras células SPEAR T

IR OVERVIEW

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

 

Recent News

More >>
Date Title  
Toggle Summary Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform - - Astellas will pay Adaptimmune an upfront payment, research funding,
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform - - Astellas will pay Adaptimmune an upfront payment, research funding,
Toggle Summary Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials PHILADELPHIA and OXFORDSHIRE, United Kingdom , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials PHILADELPHIA and OXFORDSHIRE, United Kingdom , Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune
Toggle Summary Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors - PHILADELPHIA and OXFORDSHIRE, United Kingdom , Jan.
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors - PHILADELPHIA and OXFORDSHIRE, United Kingdom , Jan.
Toggle Summary Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options PHILADELPHIA and OXFORDSHIRE, United Kingdom , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options PHILADELPHIA and OXFORDSHIRE, United Kingdom , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just click here.